III期-话题@MedSci

#III期#

681篇内容 | 2811人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594787, encodeId=072e1594e8797, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=鞘氨醇激酶2抑制剂Opaganib治疗COVID-19：II/III期研究已在墨西哥获得批准, objectType=article, longId=199330, objectId=176519933069, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=176519933069, replyNumber=0, likeNumber=59, createdTime=2020-08-14, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=176519933069, moduleTitle=鞘氨醇激酶2抑制剂Opaganib治疗COVID-19：II/III期研究已在墨西哥获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=176519933069)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594786, encodeId=86c51594e8687, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期, objectType=article, longId=199310, objectId=a5e8199310d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5e8199310d0, replyNumber=0, likeNumber=12, createdTime=2020-08-14, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5e8199310d0, moduleTitle=食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5e8199310d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594785, encodeId=c0f01594e85ec, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期, objectType=article, longId=199268, objectId=b8ff199268d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8ff199268d0, replyNumber=0, likeNumber=13, createdTime=2020-08-13, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8ff199268d0, moduleTitle=胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8ff199268d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594784, encodeId=5d191594e8400, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=etrolizumab治疗溃疡性结肠炎：III期结果并不乐观, objectType=article, longId=199178, objectId=e1f71991e85b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1f71991e85b, replyNumber=0, likeNumber=51, createdTime=2020-08-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1f71991e85b, moduleTitle=etrolizumab治疗溃疡性结肠炎：III期结果并不乐观, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1f71991e85b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594783, encodeId=aeac1594e832f, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验, objectType=article, longId=199161, objectId=739d19916169, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=739d19916169, replyNumber=0, likeNumber=13, createdTime=2020-08-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=739d19916169, moduleTitle=CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=739d19916169)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594782, encodeId=375b1594e82b6, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人, objectType=article, longId=199076, objectId=63ee1990e68c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63ee1990e68c, replyNumber=0, likeNumber=58, createdTime=2020-08-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63ee1990e68c, moduleTitle=2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63ee1990e68c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594781, encodeId=6f881594e8100, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=阿斯利康的IL-5受体单抗Fasenra：III期临床证实在嗜酸性哮喘中具有强大疗效, objectType=article, longId=198911, objectId=81e1198911ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81e1198911ce, replyNumber=0, likeNumber=73, createdTime=2020-08-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81e1198911ce, moduleTitle=阿斯利康的IL-5受体单抗Fasenra：III期临床证实在嗜酸性哮喘中具有强大疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81e1198911ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594779, encodeId=92d21594e797e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=达格列净III期DAPA-CKD试验达到所有主要终点和次要终点, objectType=article, longId=198399, objectId=7f8819839938, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f8819839938, replyNumber=0, likeNumber=62, createdTime=2020-08-01, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f8819839938, moduleTitle=达格列净III期DAPA-CKD试验达到所有主要终点和次要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f8819839938)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594778, encodeId=664f1594e78cd, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=基因疗法beremagene geperpavec治疗营养不良性大疱性表皮松解症：即将开展III期临床, objectType=article, longId=198352, objectId=6b7c198352b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b7c198352b0, replyNumber=0, likeNumber=70, createdTime=2020-07-31, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b7c198352b0, moduleTitle=基因疗法beremagene geperpavec治疗营养不良性大疱性表皮松解症：即将开展III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b7c198352b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594777, encodeId=59031594e7712, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Relacorilant治疗库欣综合症：已开展III期试验, objectType=article, longId=198329, objectId=dfc319832925, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfc319832925, replyNumber=0, likeNumber=54, createdTime=2020-07-31, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfc319832925, moduleTitle=Relacorilant治疗库欣综合症：已开展III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfc319832925)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594776, encodeId=5ae11594e76fd, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Nat Med：III期试验发现，二甲双胍提高了接受过颅脑放疗儿童脑瘤患者的工作记忆和陈述记忆, objectType=article, longId=198304, objectId=78bd19830463, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78bd19830463, replyNumber=0, likeNumber=58, createdTime=2020-07-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78bd19830463, moduleTitle=Nat Med：III期试验发现，二甲双胍提高了接受过颅脑放疗儿童脑瘤患者的工作记忆和陈述记忆, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78bd19830463)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594775, encodeId=c5161594e7596, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle= Lancet Diabetes Endo：Osilodrostat治疗库欣病III期临床获得成功, objectType=article, longId=198290, objectId=25df198290b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25df198290b5, replyNumber=0, likeNumber=12, createdTime=2020-07-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25df198290b5, moduleTitle= Lancet Diabetes Endo：Osilodrostat治疗库欣病III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25df198290b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594780, encodeId=ed751594e8088, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=COVID-19疫苗BNT162b2进入II / III期临床研究, objectType=article, longId=198193, objectId=ccfa198193ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccfa198193ff, replyNumber=0, likeNumber=56, createdTime=2020-07-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccfa198193ff, moduleTitle=COVID-19疫苗BNT162b2进入II / III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccfa198193ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594774, encodeId=59241594e74d0, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=双重PPAR激动剂治疗非酒精性脂肪性肝炎：III期临床宣布失败, objectType=article, longId=197999, objectId=2c2219e999bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c2219e999bb, replyNumber=0, likeNumber=59, createdTime=2020-07-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c2219e999bb, moduleTitle=双重PPAR激动剂治疗非酒精性脂肪性肝炎：III期临床宣布失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c2219e999bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594773, encodeId=c90e1594e730e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=JAK抑制剂Rinvoq治疗特应性皮炎：III期临床疗效显著, objectType=article, longId=197968, objectId=d9bf19e9686d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9bf19e9686d, replyNumber=0, likeNumber=47, createdTime=2020-07-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9bf19e9686d, moduleTitle=JAK抑制剂Rinvoq治疗特应性皮炎：III期临床疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9bf19e9686d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594772, encodeId=d2ec1594e72ee, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=右美托咪定舌下薄膜BXCL501治疗精神分裂症：III期临床成功, objectType=article, longId=197879, objectId=2bb519e879bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bb519e879bc, replyNumber=0, likeNumber=61, createdTime=2020-07-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bb519e879bc, moduleTitle=右美托咪定舌下薄膜BXCL501治疗精神分裂症：III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bb519e879bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594771, encodeId=2ee81594e71b7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, objectType=article, longId=197732, objectId=5be919e73267, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5be919e73267, replyNumber=0, likeNumber=73, createdTime=2020-07-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5be919e73267, moduleTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5be919e73267)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594770, encodeId=194f1594e70bb, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验, objectType=article, longId=197670, objectId=9e0019e6706c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e0019e6706c, replyNumber=0, likeNumber=94, createdTime=2020-07-19, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e0019e6706c, moduleTitle=NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e0019e6706c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594769, encodeId=78c71594e69a0, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Brilinta联合阿司匹林：III期研究证实继发性中风死亡率降低17%, objectType=article, longId=197637, objectId=bcef19e637ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bcef19e637ac, replyNumber=0, likeNumber=92, createdTime=2020-07-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bcef19e637ac, moduleTitle=Brilinta联合阿司匹林：III期研究证实继发性中风死亡率降低17%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bcef19e637ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594768, encodeId=9b311594e6807, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=靶向Aβ的阿尔茨海默症新药BAN2401，开始III期临床研究, objectType=article, longId=197608, objectId=a82f19e608e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a82f19e608e8, replyNumber=0, likeNumber=9, createdTime=2020-07-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a82f19e608e8, moduleTitle=靶向Aβ的阿尔茨海默症新药BAN2401，开始III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a82f19e608e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

鞘氨醇激酶2抑制剂Opaganib治疗COVID-19：II/III期研究已在墨西哥获得批准

2020-08-14

智智灵药 (审核中...)

前往app查看评论内容

#III期#

食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期

2020-08-14

智智灵药 (审核中...)

前往app查看评论内容

#III期#

胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期

2020-08-13

智智灵药 (审核中...)

前往app查看评论内容

#III期#

etrolizumab治疗溃疡性结肠炎：III期结果并不乐观

2020-08-12

智智灵药 (审核中...)

前往app查看评论内容

#III期#

CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验

2020-08-12

智智灵药 (审核中...)

前往app查看评论内容

#III期#

2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人

2020-08-11

智智灵药 (审核中...)

前往app查看评论内容

#III期#

阿斯利康的IL-5受体单抗Fasenra：III期临床证实在嗜酸性哮喘中具有强大疗效

2020-08-08

智智灵药 (审核中...)

前往app查看评论内容

#III期#

达格列净III期DAPA-CKD试验达到所有主要终点和次要终点

2020-08-01

智智灵药 (审核中...)

前往app查看评论内容

#III期#

基因疗法beremagene geperpavec治疗营养不良性大疱性表皮松解症：即将开展III期临床

2020-07-31

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Relacorilant治疗库欣综合症：已开展III期试验

2020-07-31

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Nat Med：III期试验发现，二甲双胍提高了接受过颅脑放疗儿童脑瘤患者的工作记忆和陈述记忆

2020-07-30

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Lancet Diabetes Endo：Osilodrostat治疗库欣病III期临床获得成功

2020-07-30

智智灵药 (审核中...)

前往app查看评论内容

#III期#

COVID-19疫苗BNT162b2进入II / III期临床研究

2020-07-30

智智灵药 (审核中...)

前往app查看评论内容

#III期#

双重PPAR激动剂治疗非酒精性脂肪性肝炎：III期临床宣布失败

2020-07-26

智智灵药 (审核中...)

前往app查看评论内容

#III期#

JAK抑制剂Rinvoq治疗特应性皮炎：III期临床疗效显著

2020-07-25

智智灵药 (审核中...)

前往app查看评论内容

#III期#

右美托咪定舌下薄膜BXCL501治疗精神分裂症：III期临床成功

2020-07-23

智智灵药 (审核中...)

前往app查看评论内容

#III期#

牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx

2020-07-20

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验

2020-07-19

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Brilinta联合阿司匹林：III期研究证实继发性中风死亡率降低17%

2020-07-18

智智灵药 (审核中...)

前往app查看评论内容

#III期#

靶向Aβ的阿尔茨海默症新药BAN2401，开始III期临床研究

2020-07-17

科室
- - 订阅+
  - 更多科室
工具
服务